Brief: Prelude, Incyte Sign Exclusive Option Deal To Advance JAK2V617F JH2 Inhibitors For Cancer Therapy

Incyte

04/11/2025 12:44

Nov 4 (Reuters) - Prelude Therapeutics Inc PRLD.O:

PRELUDE THERAPEUTICS ANNOUNCES EXCLUSIVE OPTION AGREEMENT WITH INCYTE TO ADVANCE MUTANT SELECTIVE JAK2V617F JH2 INHIBITORS

PRELUDE THERAPEUTICS INC - TO RECEIVE $35 MILLION UPFRONT, $25 MILLION EQUITY INVESTMENT

PRELUDE THERAPEUTICS INC - INCYTE TO PURCHASE 6.25 MILLION SHARES OF PRELUDE AT $4.00 EACH

PRELUDE THERAPEUTICS: TO GET $100 MILLION IF INCYTE WERE TO EXERCISE OPTION TO BUY PROGRAM

PRELUDE THERAPEUTICS: TO GET UP TO $775 MILLION IN ADDITIONAL POTENTIAL MILESTONES PLUS ROYALTIES ON NET SALES

Source text: ID:nGNX6Zk0dH

Further company coverage: PRLD.O

 ((Reuters.Briefs@thomsonreuters.com;))